JP2017513892A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513892A5
JP2017513892A5 JP2016564087A JP2016564087A JP2017513892A5 JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5 JP 2016564087 A JP2016564087 A JP 2016564087A JP 2016564087 A JP2016564087 A JP 2016564087A JP 2017513892 A5 JP2017513892 A5 JP 2017513892A5
Authority
JP
Japan
Prior art keywords
methyl
hydroxy
methylsulfonyl
propanamide
dihydroisoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564087A
Other languages
English (en)
Japanese (ja)
Other versions
JP6514716B2 (ja
JP2017513892A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/027009 external-priority patent/WO2015164458A1/en
Publication of JP2017513892A publication Critical patent/JP2017513892A/ja
Publication of JP2017513892A5 publication Critical patent/JP2017513892A5/ja
Application granted granted Critical
Publication of JP6514716B2 publication Critical patent/JP6514716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564087A 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体 Expired - Fee Related JP6514716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982467P 2014-04-22 2014-04-22
US61/982,467 2014-04-22
PCT/US2015/027009 WO2015164458A1 (en) 2014-04-22 2015-04-22 Isoxazoline hydroxamic acid derivatives as lpxc inhibitors

Publications (3)

Publication Number Publication Date
JP2017513892A JP2017513892A (ja) 2017-06-01
JP2017513892A5 true JP2017513892A5 (enExample) 2018-05-24
JP6514716B2 JP6514716B2 (ja) 2019-05-15

Family

ID=53059459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564087A Expired - Fee Related JP6514716B2 (ja) 2014-04-22 2015-04-22 LpxC阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体

Country Status (6)

Country Link
US (2) US9637482B2 (enExample)
EP (1) EP3134401B1 (enExample)
JP (1) JP6514716B2 (enExample)
CN (1) CN106573924B (enExample)
ES (1) ES2687393T3 (enExample)
WO (1) WO2015164458A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018124788A (ru) * 2015-12-08 2020-01-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Замещенные бензазиноны в качестве антибактериальных соединений
CA3026356A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
AU2017337946B2 (en) * 2016-09-28 2020-05-07 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
MX2021005966A (es) * 2018-11-21 2021-07-06 Taisho Pharmaceutical Co Ltd Nuevo derivado de imidazol.
JP2022516571A (ja) * 2019-01-06 2022-02-28 プソマーゲン, インコーポレイテッド Htra阻害物質及びcaga阻害物質並びに同物質の使用
WO2024067812A1 (zh) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途
WO2024153173A1 (zh) * 2023-01-19 2024-07-25 浙江海正药业股份有限公司 芳香乙炔类衍生物及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL314605A1 (en) * 1993-11-26 1996-09-16 Pfizer Isoxazolin compounds as anti-inflammatory agents
US7125870B2 (en) 2002-11-06 2006-10-24 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
SG2012000667A (en) 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
CA2774250C (en) * 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
PL2512474T3 (pl) 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
CN103717582B (zh) * 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物
KR20120137094A (ko) * 2011-06-10 2012-12-20 현대자동차주식회사 차량용 소음기
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Similar Documents

Publication Publication Date Title
JP2017513892A5 (enExample)
HRP20192009T1 (hr) Spojevi izoksazol hidroksamske kiseline kao inhibitori lpxc-a
ES2535244T3 (es) Compuestos heterocíclicos adecuados para el tratamiento de dislipidemia
RU2016117941A (ru) Фениколовые противобактериальные средства
JP2021504443A5 (enExample)
JP2012502946A5 (enExample)
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
JP2020502111A5 (enExample)
JP2019517455A5 (enExample)
IL264982B (en) (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP2013521286A5 (enExample)
JP2007525516A5 (enExample)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
HRP20170422T1 (hr) 3-(2-aril-cikloalkenilmetil)-oksazolidin-2-on derivati kao inhibitori transportnog proteina estera kolesterola (cetp)
JP2015508749A5 (enExample)
JP2010516715A5 (enExample)
JP2016535758A5 (enExample)
JP2017511329A5 (enExample)
HRP20190668T1 (hr) Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori
IL273000B2 (en) Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1)
JP2017505293A5 (enExample)
JP2015536974A5 (enExample)
RU2012142171A (ru) Ингибиторы катехол-о-метилтрансферазы и их применение в лечении психических расстройств
RU2015116540A (ru) Замещенные соединения спиропиперидинила, применяемые в качестве агонистов gpr120
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1